Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Revolution Medicines, Inc.
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07349537CT.gov Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors | — | Recruiting | — | — | — |
NCT07300150CT.gov A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05395052CT.gov FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors | — | Terminated | — | — | — |
NCT04956640CT.gov Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) | — | Active Not Recruiting | — | — | — |
NCT04464967CT.gov Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | — | Withdrawn | — | — | — |
NCT03319459CT.gov FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors | — | Completed | — | — | — |
NCT02241187CT.gov Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection | — | Completed | — | — | — |
NCT00923299CT.gov Cetuximab and Trastuzumab in Treating Patients With Metastatic Pancreatic Cancer That Progressed After Previous Treatment With Gemcitabine | — | Completed | — | — | — |
NCT00871169CT.gov Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer | — | Completed | — | — | — |
NCT00599833CT.gov Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery | — | Completed | — | — | — |
Show 13 more trialsShow fewer
NCT00424827CT.gov A Trial of Chemo & Radiation Therapy for Pancreatic Cancer | — | Completed | — | — | — |
NCT00448838CT.gov Cetuximab, Gemcitabine, and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | — | Completed | — | — | — |
NCT00408564CT.gov Cetuximab, Gemcitabine, and Oxaliplatin Followed By Surgery or External-Beam Radiation Therapy and Capecitabine in Treating Patients With Locally Advanced, Nonmetastatic Pancreatic Cancer That Cannot Be Removed By Surgery | — | Completed | — | — | — |
NCT00305760CT.gov Vaccine Therapy, Cyclophosphamide, and Cetuximab in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer | — | Completed | — | — | — |
NCT00622674CT.gov Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT00276744CT.gov Individualized Drug Treatment for Treating Patients With Pancreatic Cancer | — | Terminated | — | — | — |
NCT00467116CT.gov PhI Study of Erbitux & Gemcitabine w/Radiation Therapy for Locally Adv. Pancreas Ca | — | Completed | — | — | — |
NCT00338039CT.gov Induction Cetuximab (IM-C225), Gemcitabine, and Oxaliplatin in Pancreatic Cancer Patients | — | Completed | — | — | — |
NCT00536614CT.gov Gemcitabine/Cisplatin +/-Cetuximab in Patients With Locally Advanced or Metastatic EGFR-Positive Pancreatic Cancer | — | Completed | — | — | — |
NCT00225784CT.gov Cetuximab, Radiotherapy and Twice Weekly Gemcitabine to Treat Pancreatic Cancer | — | Completed | — | — | — |
NCT00075686CT.gov S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer | — | Completed | — | — | — |
NCT00042939CT.gov Irinotecan and Docetaxel With or Without Cetuximab in Treating Patients With Metastatic Pancreatic Cancer | — | Completed | — | — | — |
NCT00005591CT.gov Cetuximab Plus Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Cancer of the Pancreas | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Pancreatic Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cetuximab (this asset) | Revolution Medicines, Inc. | P3 | B · 60 |
| Tinzaparin | Helsinki University Central Hospital | P4 | BBB |
| Oxaliplatin | Memorial Sloan Kettering Cancer Center | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | Taiho Oncology, Inc. | P3 | BB |
| Fluorouracilum | Memorial Sloan Kettering Cancer Center | P3 | BB |
| Capecitabine | Tianjin Medical University Cancer Institute and Hospital | P3 | BB |
| Irinotecan | Memorial Sloan Kettering Cancer Center | P3 | BB |
| Triglycerides,Medium Chain | Wei Zhou | P4 | BB |
| Desflurane | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | P4 | BB |
+42 more in the Pancreatic Neoplasm cohort
Other indications for Cetuximab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Colon Adenocarcinoma | — | P3 | BB · 70 |
| Rectal Carcinoma | — | P2 | BB · 69 |
| Non-Small Cell Lung Carcinoma | — | P3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cetuximab in Pancreatic Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cetuximab-pancreatic-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →